Hubert Pehamberger Selected Research

HMW-MAA

5/2011	Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity.
12/2008	Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine.
7/2005	High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
4/2005	Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.
4/2005	Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.
1/2005	Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hubert Pehamberger Research Topics

Disease

59	Melanoma (Melanoma, Malignant) 01/2019 - 04/2002
44	Neoplasms (Cancer) 02/2015 - 04/2002
20	Neoplasm Metastasis (Metastasis) 01/2016 - 12/2003
5	Nevus (Nevi) 01/2015 - 04/2003
4	Breast Neoplasms (Breast Cancer) 05/2011 - 12/2003
3	Lymphatic Metastasis 01/2013 - 09/2004
3	Neuroblastoma 05/2011 - 02/2005
2	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2016 - 12/2006
2	Disease Progression 09/2015 - 01/2014
2	Skin Diseases (Skin Disease) 09/2015 - 12/2006
2	Skin Neoplasms (Skin Cancer) 02/2015 - 12/2011
2	Systemic Mastocytosis 01/2014 - 09/2010
2	Infections 01/2014 - 10/2006
2	Carcinogenesis 12/2011 - 08/2004
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 10/2008 - 08/2005
2	Cutaneous Malignant Melanoma 10/2006 - 10/2003
2	Sarcoma (Soft Tissue Sarcoma) 05/2006 - 06/2004
1	Necrosis 02/2016
1	Extranodal Extension 11/2015
1	Genetic Translocation (Chromosomal Translocation) 11/2015
1	Sclerosis 07/2015
1	Lung Neoplasms (Lung Cancer) 07/2015
1	Systemic Scleroderma (Systemic Sclerosis) 07/2015
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2015
1	Inflammation (Inflammations) 02/2015
1	Hepatitis 01/2014
1	Chronic Hepatitis C 01/2014
1	Mastocytosis 01/2013
1	Neoplasm Micrometastasis 01/2013
1	COVID-19 related adult multisystem inflammatory disease 01/2013

Drug/Important Bio-Agent (IBA)

19	Proteins (Proteins, Gene)FDA Link 01/2019 - 12/2002
8	Peptides (Polypeptides)IBA 05/2011 - 10/2002
8	Antisense OligonucleotidesIBA 10/2006 - 09/2002
6	Monoclonal AntibodiesIBA 08/2012 - 10/2002
6	VaccinesIBA 05/2011 - 07/2004
6	HMW-MAAIBA 05/2011 - 01/2005
6	EpitopesIBA 05/2011 - 10/2002
6	AntibodiesIBA 05/2011 - 12/2003
5	ProteomeIBA 01/2019 - 05/2009
5	Pharmaceutical PreparationsIBA 02/2016 - 11/2007
5	InterferonsIBA 01/2016 - 10/2012
5	Biological ProductsIBA 07/2010 - 01/2004
5	Dacarbazine (DIC)FDA LinkGeneric 04/2010 - 06/2003
5	OligonucleotidesIBA 06/2005 - 05/2002
4	Interferon-alpha (Interferon Alfa)IBA 01/2014 - 10/2004
4	AntigensIBA 01/2014 - 12/2003
3	Vascular Endothelial Growth Factor CIBA 01/2015 - 09/2012
3	Immunoglobulin G (IgG)IBA 12/2008 - 12/2003
3	Interleukin-12 (IL 12)IBA 11/2007 - 12/2002
3	oblimersen (G3139)IBA 10/2006 - 12/2002
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2015 - 12/2003
2	Indicators and Reagents (Reagents)IBA 09/2015 - 04/2005
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2015 - 05/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 05/2009
2	Biomarkers (Surrogate Marker)IBA 01/2015 - 05/2009
2	Surface Antigens (Surface Antigen)IBA 01/2014 - 11/2010
2	Imatinib Mesylate (Gleevec)FDA Link 01/2014 - 09/2010
2	Cisplatin (Platino)FDA LinkGeneric 07/2013 - 05/2002
2	Epidermal Growth Factor (EGF)IBA 01/2013 - 10/2006
2	IpilimumabIBA 08/2012 - 12/2011
2	LigandsIBA 01/2012 - 01/2004
2	DNA (Deoxyribonucleic Acid)IBA 09/2011 - 10/2004
2	Neoplasm Antigens (Tumor Antigens)IBA 05/2011 - 02/2005
2	Heme Oxygenase-1IBA 07/2010 - 09/2006
2	Dimethyl FumarateIBA 04/2010 - 12/2006
2	Phosphotransferases (Kinase)IBA 02/2010 - 12/2002
2	matrigelIBA 05/2009 - 06/2005
2	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 12/2006 - 06/2004
2	Messenger RNA (mRNA)IBA 12/2006 - 06/2005
2	dinutuximabIBA 05/2006 - 02/2005
2	Trastuzumab (Herceptin)FDA Link 07/2004 - 12/2003
1	Type 1 Melanocortin ReceptorIBA 01/2016
1	Cetuximab (Erbitux)FDA Link 09/2015
1	Extracellular Matrix ProteinsIBA 03/2015
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2015
1	ResveratrolIBA 03/2015
1	VemurafenibIBA 03/2015
1	Inhibins (Inhibin)IBA 01/2015
1	activin AIBA 01/2015
1	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2014
1	Nerve Growth Factor (NGF)IBA 01/2014
1	CytokinesIBA 01/2014
1	Adapalene (Differin)FDA LinkGeneric 01/2014
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2014
1	Tetraspanin 30IBA 01/2014
1	CaspasesIBA 04/2013
1	birinapantIBA 04/2013
1	Inhibitor of Apoptosis ProteinsIBA 04/2013
1	Tryptases (Tryptase)IBA 01/2013
1	peginterferon alfa-2b (Pegintron)FDA Link 01/2013
1	Interferon alpha-2 (Roferon-A)FDA Link 01/2013

Therapy/Procedure

15	Therapeutics 01/2016 - 05/2002
10	Heterologous Transplantation (Xenotransplantation) 05/2009 - 04/2002
6	Drug Therapy (Chemotherapy) 10/2006 - 05/2002
4	Immunotherapy 12/2008 - 12/2003
3	Subcutaneous Injections 06/2005 - 02/2004
1	Adjuvant Radiotherapy 11/2015
1	Combination Drug Therapy (Combination Chemotherapy) 09/2015
1	Photopheresis 07/2015
1	Lasers (Laser) 01/2013